$1.54
1.60%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US02155H2004
Symbol
ALT

Altimmune Stock News

Neutral
●
GlobeNewsWire
●
6 days ago
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, N.J.
Neutral
●
GlobeNewsWire
●
6 days ago
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
Neutral
●
GlobeNewsWire
●
8 days ago
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
Neutral
●
GlobeNewsWire
●
12 days ago
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
Neutral
●
GlobeNewsWire
●
22 days ago
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.
Neutral
●
GlobeNewsWire
●
about 2 months ago
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
Neutral
●
GlobeNewsWire
●
3 months ago
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today